FGFR3基因单核苷酸多态与绝经前乳腺癌易感性的关联研究

doi:10.11904/j.issn.1002-3070.2017.05.006

摘要/Abstract

摘要： 目的探讨FGFR3基因单核苷酸多态(SNPs)与女性绝经前乳腺癌的风险关系。方法采用多重单碱基延伸SNP分型技术(Snapshot)检测FGFR3基因的rs2234909和rs3135848的SNP基因型在绝经前乳腺癌患者和绝经前正常女性人群中的频率,并分析不同SNP基因型与绝经前乳腺癌发病的风险关系。结果 FGFR3基因rs2234909和rs3135848的SNP基因型的频率在乳腺癌与对照组间无统计学差异(P＞0.05)。Logistic回归分析结果显示,对于rs2234909位点,相比较于TT基因型,TC和TC+CC基因型和乳腺癌的发病风险无显著相关性(OR=1.035,95% CI:0.680~1.575,P=0.874;OR=0.985,95% CI:0.638~1.521,P=0.945);对于rs3135848位点,相比较于TT基因型,TC、CC和TC+CC基因型与乳腺癌的发病风险无关(OR=1.177,95% CI:0.846~1.636,P=0.333;OR=0.948,95% CI:0.287~3.137,P=0.931;OR=1.162,95% CI:0.548~1.112,P=0.360)。rs2234909位点突变的乳腺癌患者与未突变者相比,组织学分级(显性模型:P=0.032;共显性模型:P=0.024)以及Ki67指数(显性模型:P=0.056;共显性模型:P=0.044)显著增高;rs3135848位点突变及两位点均突变与乳腺癌患者临床病理特征无显著相关性(P＞0.05)。结论 FGFR3基因的rs2234909和rs3135848两位点基因多态性与乳腺癌易感性无明显相关性;而rs2234909位点突变在绝经前乳腺癌患者中与组织学分级和Ki67指数呈正相关,可能提示预后不良。

关键词: 乳腺癌, FGFR3基因, 单核苷酸多态, 遗传易感性

Abstract: Objective The aim of this study was to investigate the association between single nucleotide polymorphisms(SNPs)in FGFR3 gene and the risk of breast cancer.Methods The frequency of SNP genotypes rs2234909 and rs3135848 of FGFR3 gene in premenopausal breast cancer patients and premenopausal normal females were detected by multiple clonal extension SNP typing technique.The SNP genotypes were compared with different SNP genotypes and the risk of premenopausal breast cancer.Results There was no difference in the genotype frequencies of SNP rs2234909 and rs3135848 between breast cancer and control groups(P＞0.05).Logistic regression analysis showed that there was no correlation between TC and TC +CC genotype and risk of breast cancer(OR=1.035,95% CI:0.680~1.575,P=0.874;OR=0.985,95% CI:0.638~1.521,P=0.945).For the rs3135848 locus,the genotypes of TC,CC and TC+CC were not associated with the risk of breast cancer(OR=1.177,95% CI:0.846-1.636,P=0.333;OR=0.948,95% CI:0.287-3.137,P=0.931;OR=1.162,95% CI:0.548~1.112,P=0.360).Histological grade was significantly higher in breast cancer with rs2234909 mutation than that of the non-mutation group(dominant model:P=0.032,co-dominant model:P=0.024).The Ki67 index of FGFR3 gene locus rs2234909 mutation was higher than that of the non-mutation(dominant model:P=0.056;co-dominant model:P=0.044).There was no difference between rs3135848 mutation and both site mutation with clinicopathological features of breast cancer patients(P＞0.05).Conclusion The SNP genotypes of rs2234909 and rs3135848 of FGFR3 gene were not associated with susceptibility to breast cancer in premenopausal women in North of China.Rs2234909 mutation was positively correlated with histological grade and Ki67 index in premenopausal breast cancer patients.

Key words: Breast cancer, FGFR3 gene, Single nucleotide polymorphism, Genetic susceptibility

中图分类号:

R737.9

李伟, 姜永冬, 庞达. FGFR3基因单核苷酸多态与绝经前乳腺癌易感性的关联研究[J]. 实用肿瘤学杂志, 2017, 31(5): 417-424.

LI Wei, JIANG Yongdong, PANG Da. Association between single nucleotide polymorphisms in FGFR3 gene and risk of breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 417-424.

参考文献

1 Siegel RL,Miller KD,Jemal A.Cancer statistics,2017[J].CA Cancer J Clin,2017,67(1):7-30.
2 Fan L,Strasser-Weippl K,Li JJ,et al.,Breast cancer in China[J].Lancet Oncol,2014,15(7):279-289.
3 Kwong A,Shin VY,Ho JC,et al.Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries[J].J Med Genet,2016,53(1):15-23.
4 Helsten T,Schwaederle M,Kurzrock R.Fibroblast growth factor receptor signaling in hereditary and neoplastic disease:biologic and clinical implications[J].Cancer Metastasis Rev,2015,34(3):479-496.
5 Katoh M.FGFR inhibitors:Effects on cancer cells,tumor microenvironment and whole-body homeostasis(Review)[J].Int J Mol Med,2016,38(1):3-15.
6 Parker BC,Engels M,Annala M,et al.Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours[J].J Pathol,2014,232(1):4-15.
7 Phipps AI,Ichikawa L,Bowles EJ,et al.Defining menopausal status in epidemiologic studies:A comparison of multiple approaches and their effects on breast cancer rates[J].Maturitas,2010,67(1):60-66.
8 Wang J,Yang DL,Chen ZZ,et al.Associations of body mass index with cancer incidence among populations,genders,and menopausal status:A systematic review and meta-analysis[J].Cancer Epidemiol,2016,42:1-8.
9 Lafitte M,Moranvillier I,Garcia S,et al.FGFR3 has tumor suppressor properties in cells with epithelial phenotype[J].Mol Cancer,2013,12:83.
10 Chellaiah AT,McEwen DG,Werner S,et al.Fibroblast growth factor receptor(FGFR)3.Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1[J].J Biol Chem,1994,269(15):11620-11627.
11 Pannier S,Couloigner V,Messaddeq N,et al.Activating Fgfr3 Y367C mutation causes hearing loss and inner ear defect in a mouse model of chondrodysplasia[J].Biochim Biophys Acta,2009,1792(2):140-147.
12 Pannier S,Mugniery E,Jonquoy A,et al.Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia[J].Bone,2010,47(5):905-915.
13 Kanazawa TY,Bonadia LC,Cavalcanti DP.Frequency of the allelic variant c.1150T ＞ C in exon 10 of the fibroblast growth factor receptor 3(FGFR3)gene is not increased in patients with pathogenic mutations and related chondrodysplasia phenotypes[J].Genet Mol Biol,2014,37(4):622-624.
14 Lindy AS,Basehore MJ,Munisha M,et al.Identification of a novel insertion mutation in FGFR3 that causes thanatophoric dysplasia type 1[J].Am J Med Genet A,2016,170(6):1573-1579.
15 Del Piccolo N,Placone J,Hristova K.Effect of thanatophoric dysplasia type I mutations on FGFR3 dimerization[J].Biophys J,2015,108(2):272-278.
16 Onwuazor ON,Wen XY,Wang DY,et al.Mutation,SNP,and isoform analysis of fibroblast growth factor receptor 3(FGFR3)in 150 newly diagnosed multiple myeloma patients[J].Blood,2003,102(2):772-773.
17 Saez B,Martin-Subero JI,Lahortiga I,et al.Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma:lack of concurrent activation of both proto-oncogenes[J].Cancer Genet Cytogenet,2007,175(1):65-68.
18 Christensen E,Birkenkamp-Demtroder K,Nordentoft I,et al.Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer[J].Eur Urol,2017,71(6):961-969.
19 Chou A,Dekker N,Jordan RC.Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip[J].Oral Surg Oral Med Oral Pathol Oral Radiol Endod,2009,107(4):535-541.
20 Zhang Y,Hiraishi Y,Wang H,et al.Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas[J].Int J Cancer,2005,117(1):166-168.
21 Kogita A,Yoshioka Y,Sakai K,et al.Inter-and intra-tumor profiling of multi-regional colon cancer and metastasis[J].Biochem Biophys Res Commun,2015,458(1):52-56.
22 Zammit C,Barnard R,Gomm J,et al.Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer[J].J Pathol,2001,194(1):27-34.
23 Johnston CL,Cox HC,Gomm JJ,et al.Fibroblast growth factor receptors(FGFRs)localize in different cellular compartments.A splice variant of FGFR-3 localizes to the nucleus[J].J Biol Chem,1995,270(51):30643-30650.
24 Penault-Llorca F,Bertucci F,Adelaide J,et al.Expression of FGF and FGF receptor genes in human breast cancer[J].Int J Cancer,1995,61(2):170-176.
25 Agarwal D,Pineda S,Michailidou K,et al.FGF receptor genes and breast cancer susceptibility:results from the Breast Cancer Association Consortium[J].Br J Cancer,2014,110(4):1088-1100.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[3]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[4]	刘佳音,燕飞虎,张艳桥. 凋亡基因Caspase3和Caspase7单核苷酸多态性与胃癌遗传易感性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 250-255.
[5]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[6]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[7]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[8]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[9]	胡智慧综述, 张静审校. SNP对放射性肺损伤预测作用的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 87-91.
[10]	何煦, 叶尚勉, 董丹丹, 李科. HLA-G在乳腺癌中的表达及意义[J]. 实用肿瘤学杂志, 2018, 32(5): 410-414.
[11]	林荣杰, 尹航, 周云峰. ON123300对ER阳性人乳腺癌MCF-7细胞的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 193-197.
[12]	李林(综述), 李志高(审校). 二甲双胍与不同分子亚型乳腺癌的关系[J]. 实用肿瘤学杂志, 2018, 32(3): 267-270.
[13]	郑伟, 许守平, 庞达. 长链非编码RNA Linc00152在泛癌中表达、预后及功能研究[J]. 实用肿瘤学杂志, 2018, 32(1): 7-13.
[14]	殷玉莲, 张卫红, 周悦, 叶媚娜, 陈红风. ERα基因单核苷酸多态性与乳腺癌应用芳香化酶抑制剂引发骨丢失的相关性研究[J]. 实用肿瘤学杂志, 2018, 32(1): 14-18.
[15]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.